Neurocrine Biosciences, Inc. (BIT:1NBIX)

Italy flag Italy · Delayed Price · Currency is EUR
133.55
-6.05 (-4.33%)
At close: Dec 5, 2025
Market Cap 13.33B
Revenue (ttm) 2.29B
Net Income (ttm) 364.78M
Shares Out n/a
EPS (ttm) 3.57
PE Ratio 36.54
Forward PE 16.25
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 2
Open n/a
Previous Close 139.60
Day's Range n/a
52-Week Range 92.16 - 139.60
Beta n/a
RSI 55.80
Earnings Date Feb 9, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1992
Employees 1,800
Stock Exchange Borsa Italiana
Ticker Symbol 1NBIX
Full Company Profile

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD Financial Statements

News

There is no news available yet.